Race Oncology Secures human ethics trial approval
- Race Oncology (RAC) receives human ethics approval for the next stage of its clinical trial of Zantrene in breast cancer patients
- The company received the approval from the Hunter New England Human Research Ethics Committee for the observational stage of a planned phase 1/2b cardioprotection clinical program using Zantrene
- The company must now submit and receive research institutional governance approval before patients can be enrolled and treated in the study
- Race says the human trials will be fully funded from its December 2021 capital raise
- RaceOncology is up 3.99 per cent, trading at $1.96 at 2:51 pm AEDT
